News

By Giovanna Verginelli Mezher

Life Sciences Brazil Global Guide 2025 | Chambers & Partners

We are pleased to announce our collaboration on the Chambers and Partners Life Sciences 2025 Global Practice Guide!

Our partners Priscila Kashiwabara and Viviane Trojan, along with attorneys Gustavo Vicenti and Giovanna Verginelli Mezher, authored the Life Sciences 2025 guide for Brazil. This guide outlines the regulatory framework for pharmaceuticals and medical devices, detailing legislation, regulatory bodies, and procedures for approvals and appeals. It covers categorization, clinical trials, marketing authorizations, and ongoing obligations.

The guide also emphasizes ANVISA’s role in regulation, stringent requirements for biologics, and procedures for compassionate use and post-marketing surveillance. Additionally, it addresses manufacturing authorizations, distribution regulations, and measures against counterfeit products.

Click here to read the full article: https://lnkd.in/dbU5yrvD.

Back

Last by Giovanna Verginelli Mezher

4 de November de 2025

ANVISA Publishes New Proposal for Review of the Regulation on General Labeling of Packaged Foods: Public Consultation No. 1357/2025

The proposal for reviewing the regulation concerning the general labeling of packaged foods (including beverages, ingredients, additives, and processing aids) was published ANVISA Publishes New Proposal for Review of the Regulation on General Labeling of Packaged Foods: Public Consultation No. 1357/2025

Ler notícia

29 de October de 2025

Lexology Panoramic: Pharma & Medical Device Regulation 2026

We are pleased to share the Brazil chapter of the Pharma & Medical Device Regulation Panoramic guide, authored by our partners Claudio Lexology Panoramic: Pharma & Medical Device Regulation 2026

Ler notícia

30 de July de 2025

Weekly Update for Intellectual Property in Health

On July 28th, 2025, the Official Gazette of the Union (DOU) published Ministerial Ordinance GM/MS No. 7,687, dated July 24, 2025, issued Weekly Update for Intellectual Property in Health

Ler notícia